Abstract
Sentinel lymph node biopsy (SLNB) is a surgical procedure that has been used in patients with cutaneous melanoma for nearly 30 years. It is used for both staging and regional disease control with minimum morbidity, as proven by numerous worldwide prospective studies. It has been incorporated in the recommendations of national and professional guidelines. In this article, we provide a summary of the general information on SLNB in the clinical guidelines for the management of cutaneous malignant melanoma (American Association of Dermatology, European Society of Medical Oncology, National Comprehensive Cancer Network, and Cancer Council Australia) and review the most relevant literature to provide an update on the existing recommendations for SLNB.
Reference85 articles.
1. Nonmelanoma Skin Cancer;Brandt;Facial. Plast. Surg. Clin. N. Am.,2019
2. Epidemiology of Melanoma;Bolick;Hematol. Oncol. Clin. N. Am.,2021
3. Malignant Melanoma: Skin Cancer-Diagnosis, Prevention, and Treatment;Ahmed;Crit. Rev. Eukaryot. Gene. Expr.,2020
4. Saginala, K., Barsouk, A., Aluru, J.S., Rawla, P., and Barsouk, A. Epidemiology of Melanoma. Med. Sci., 2021. 9.
5. Technical details of intraoperative lymphatic mapping for early-stage melanoma;Morton;Arch. Surg.,1992
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献